MX2012006902A - Supositorio de mesalamina. - Google Patents
Supositorio de mesalamina.Info
- Publication number
- MX2012006902A MX2012006902A MX2012006902A MX2012006902A MX2012006902A MX 2012006902 A MX2012006902 A MX 2012006902A MX 2012006902 A MX2012006902 A MX 2012006902A MX 2012006902 A MX2012006902 A MX 2012006902A MX 2012006902 A MX2012006902 A MX 2012006902A
- Authority
- MX
- Mexico
- Prior art keywords
- mesalamine
- suppository
- rectal
- dissolution
- usp
- Prior art date
Links
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 title claims abstract description 334
- 229960004963 mesalazine Drugs 0.000 title claims abstract description 333
- 239000000829 suppository Substances 0.000 title claims abstract description 226
- 238000004090 dissolution Methods 0.000 claims abstract description 69
- 229940079593 drug Drugs 0.000 claims abstract description 55
- 239000003814 drug Substances 0.000 claims abstract description 55
- 238000000034 method Methods 0.000 claims abstract description 47
- 239000008363 phosphate buffer Substances 0.000 claims abstract description 36
- 229940116364 hard fat Drugs 0.000 claims abstract description 32
- 239000002245 particle Substances 0.000 claims abstract description 29
- 238000002844 melting Methods 0.000 claims abstract description 27
- 230000008018 melting Effects 0.000 claims abstract description 27
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 23
- 230000001174 ascending effect Effects 0.000 claims abstract description 13
- 239000006215 rectal suppository Substances 0.000 claims description 24
- 229940100618 rectal suppository Drugs 0.000 claims description 22
- 238000007654 immersion Methods 0.000 claims description 18
- 206010036774 Proctitis Diseases 0.000 claims description 9
- 206010036783 Proctitis ulcerative Diseases 0.000 claims description 9
- 229940047968 mesalamine rectal suppository Drugs 0.000 abstract 5
- 239000000203 mixture Substances 0.000 description 27
- 239000002511 suppository base Substances 0.000 description 22
- 206010009900 Colitis ulcerative Diseases 0.000 description 15
- 201000006704 Ulcerative Colitis Diseases 0.000 description 15
- 230000008569 process Effects 0.000 description 14
- 238000002156 mixing Methods 0.000 description 13
- 239000003925 fat Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 235000019197 fats Nutrition 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 7
- 239000006185 dispersion Substances 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 208000007502 anemia Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000000155 melt Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 208000004998 Abdominal Pain Diseases 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 238000011978 dissolution method Methods 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 208000005156 Dehydration Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 208000002720 Malnutrition Diseases 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000004519 grease Substances 0.000 description 3
- 230000001071 malnutrition Effects 0.000 description 3
- 235000000824 malnutrition Nutrition 0.000 description 3
- 208000015380 nutritional deficiency disease Diseases 0.000 description 3
- 230000003134 recirculating effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 208000016261 weight loss Diseases 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 206010038063 Rectal haemorrhage Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000003960 inflammatory cascade Effects 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 229960003511 macrogol Drugs 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- -1 polyoxyethylene chain Polymers 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 201000002516 toxic megacolon Diseases 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- HDIFHQMREAYYJW-XGXNLDPDSA-N Glyceryl Ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCC(O)CO HDIFHQMREAYYJW-XGXNLDPDSA-N 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010057071 Rectal tenesmus Diseases 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 235000021471 food effect Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229940116338 glyceryl ricinoleate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 239000012803 melt mixture Substances 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 208000012271 tenesmus Diseases 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/606—Salicylic acid; Derivatives thereof having amino groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/639,645 US8436051B2 (en) | 2007-06-08 | 2009-12-16 | Mesalamine suppository |
| PCT/US2010/060849 WO2011084638A2 (en) | 2009-12-16 | 2010-12-16 | Mesalamine suppository |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012006902A true MX2012006902A (es) | 2012-10-05 |
Family
ID=43901620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012006902A MX2012006902A (es) | 2009-12-16 | 2010-12-16 | Supositorio de mesalamina. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8436051B2 (OSRAM) |
| EP (1) | EP2512443A2 (OSRAM) |
| JP (1) | JP2013514979A (OSRAM) |
| KR (1) | KR20120104604A (OSRAM) |
| CN (1) | CN102970971A (OSRAM) |
| AU (1) | AU2010339837A1 (OSRAM) |
| CA (2) | CA2690450A1 (OSRAM) |
| CL (1) | CL2012001636A1 (OSRAM) |
| IL (1) | IL220397A0 (OSRAM) |
| MX (1) | MX2012006902A (OSRAM) |
| RU (1) | RU2012125186A (OSRAM) |
| SG (1) | SG181169A1 (OSRAM) |
| WO (1) | WO2011084638A2 (OSRAM) |
| ZA (1) | ZA201204422B (OSRAM) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10323320B2 (en) | 2008-04-24 | 2019-06-18 | Oerlikon Surface Solutions Ag, Pfäffikon | Method for producing metal oxide layers of predetermined structure through arc vaporization |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8436051B2 (en) | 2007-06-08 | 2013-05-07 | Aptalis Pharma Canada Inc. | Mesalamine suppository |
| CA2810283A1 (en) * | 2010-09-10 | 2012-03-15 | Pharmazell Gmbh | Process for producing crystalline 5-aminosalicylic acid |
| WO2013059768A1 (en) * | 2011-10-20 | 2013-04-25 | Aptalis Pharma U.S., Inc. | Therapeutic agents for treating gastrointestinal disorders associated with inflammation of the gastrointestinal tract |
| CN103622974B (zh) * | 2013-12-05 | 2016-04-20 | 武汉武药科技有限公司 | 一种含美沙拉嗪和n-乙酰半胱氨酸的复方栓剂及其制备方法 |
| US20160175271A1 (en) * | 2014-12-19 | 2016-06-23 | Gavis Pharmaceuticals | Rectal suppository for ulcerative colitis |
| US10098898B1 (en) | 2017-12-04 | 2018-10-16 | Handa Pharmaceuticals, Llc | Release stable mesalamine dosage forms |
| AR120360A1 (es) * | 2019-10-31 | 2022-02-09 | Scherer Technologies Llc R P | Cápsula de supositorio |
| KR20250042058A (ko) | 2023-09-19 | 2025-03-26 | 한양대학교 산학협력단 | 염증성 장 질환 치료용 약학적 조성물 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3689514A (en) * | 1969-05-21 | 1972-09-05 | Schlueter Edelfett | Suppository vehicle and process of making same |
| US4211777A (en) * | 1977-11-25 | 1980-07-08 | Fisons Limited | Compositions comprising a compound having sodium cromoglycate activity and aminosalicylic acid |
| US4298595A (en) * | 1978-12-20 | 1981-11-03 | Dynapol | Pharmaceutical preparations containing a polymeric agent for releasing 5-aminosalicylic acid or its salts into the gastrointestinal tract |
| US4374932A (en) * | 1981-06-08 | 1983-02-22 | G. D. Searle & Co. | 5-ASA Drug delivery system |
| DE3151196A1 (de) * | 1981-12-23 | 1983-06-30 | Kurt Heinz Prof. Dr. 7800 Freiburg Bauer | Verfahren zur herstellung von gut loeslichen 5-aminosalicylsaeure-arzneimittelzubereitungen |
| JPH0816051B2 (ja) * | 1988-12-07 | 1996-02-21 | エスエス製薬株式会社 | 徐放性坐剤 |
| US5629012A (en) * | 1991-06-17 | 1997-05-13 | Farmaceutisk Laboratorium Ferring A/S | Process for producing suppositories by compression and suppositories obtained by the process |
| GB9201857D0 (en) * | 1992-01-29 | 1992-03-18 | Smithkline Beecham Plc | Novel compound |
| US5389375A (en) * | 1993-05-21 | 1995-02-14 | University Of Mississippi | Stable suppository formulations effecting bioavailability of Δ9 -thc |
| DK66493D0 (da) * | 1993-06-08 | 1993-06-08 | Ferring A S | Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling |
| ATE231388T1 (de) * | 1995-09-07 | 2003-02-15 | Taisho Pharmaceutical Co Ltd | Lang wirksames mittel zur rektalen verabreichung |
| JPH09323934A (ja) * | 1996-05-31 | 1997-12-16 | Kanebo Ltd | 保存安定性の改善された坐剤 |
| EP0971735B1 (en) | 1997-04-01 | 2008-03-19 | Thomas Julius Borody | Methods and compositions for treating inflammatory bowel disease |
| DE69824748T2 (de) * | 1997-09-26 | 2005-08-25 | Celltech Pharma Europe Ltd. | Pharmazeutische zusammensetzung für die behandlung von enzündlichen darmerkrankungen |
| JP4449213B2 (ja) * | 1997-10-08 | 2010-04-14 | 大正製薬株式会社 | 坐剤用組成物 |
| US6326364B1 (en) * | 1999-02-08 | 2001-12-04 | Cedars-Sinai Medical Center | Use of 5-aminosalicylates as antimicrobial agents |
| US6610674B1 (en) * | 1999-09-28 | 2003-08-26 | University Of Pennsylvania | Method of treating inflammatory conditions with progesterone analogs |
| US6720001B2 (en) * | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| US20020037855A1 (en) * | 2000-05-05 | 2002-03-28 | Fritz Stanislaus | Stabilized medicament containing cysteinyl derivatives |
| CA2420576C (en) * | 2000-08-29 | 2005-06-14 | Nobex Corporation | Immunoregulatory compounds, derivatives thereof and their use |
| AU2003273243A1 (en) * | 2002-08-23 | 2004-03-11 | Zymogenetics, Inc. | Method for treating inflammatory bowel disease |
| US7312243B1 (en) * | 2003-08-29 | 2007-12-25 | Jay Pravda | Materials and methods for treatment of gastrointestinal disorders |
| US7825106B2 (en) * | 2003-09-03 | 2010-11-02 | Agi Therapeutics Ltd. | Modified release formulations and methods of treating inflammatory bowel disease |
| US7417037B2 (en) * | 2004-01-20 | 2008-08-26 | The Board Of Regents Of The University Of Oklahoma | Compositions and methods of treatment for inflammatory diseases |
| EP1751096A4 (en) * | 2004-05-27 | 2009-01-07 | Antibe Therapeutics Inc | 4- OR 5- AMINOSALICYLIC ACID SALT |
| CZ296169B6 (cs) * | 2004-09-08 | 2006-01-11 | Pliva - Lachema A. S. | Farmaceutická kompozice pro rektální nebo vaginální podání, zpusob její prípravy a tato kompozice pro pouzití jako lécivo |
| WO2006035418A2 (en) * | 2004-09-27 | 2006-04-06 | Sigmoid Biotechnologies Limited | Microcapsules comprising a methylxanthine and a corticosteroid |
| US7250445B1 (en) * | 2005-01-14 | 2007-07-31 | Ehrenpreis Eli D | Anti-oxidant suppository for treating radiation proctopathy and other anorectal disorders |
| US8921344B2 (en) * | 2006-11-03 | 2014-12-30 | Salix Pharmaceuticals, Inc. | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
| CA2644889A1 (en) * | 2006-03-07 | 2007-09-13 | Combinatorx, Incorporated | Compositions and methods for the treatment of immunoinflammatory disorders |
| EP2034816A1 (en) * | 2006-04-05 | 2009-03-18 | Oklahoma Medical Research Foundation | O-glycans in the treatment of inflammatory bowel disease and cancers |
| NZ572049A (en) * | 2006-05-01 | 2012-08-31 | Napo Pharmaceuticals Inc | Method for treatment of constipation-predominant irritable bowel syndrome |
| US20070254050A1 (en) * | 2006-05-01 | 2007-11-01 | Quart Barry D | Method for treatment of diarrhea-predominant irritable bowel syndrome |
| WO2008031013A1 (en) * | 2006-09-08 | 2008-03-13 | Gene Logic Inc. | Method for treating inflammatory diseases of the digestive tract |
| US8436051B2 (en) | 2007-06-08 | 2013-05-07 | Aptalis Pharma Canada Inc. | Mesalamine suppository |
| US8217083B2 (en) * | 2007-06-08 | 2012-07-10 | Aptalis Pharma Canada Inc. | Mesalamine suppository |
| US7541384B2 (en) * | 2007-06-08 | 2009-06-02 | Axcan Pharma Inc. | Mesalamine suppository |
-
2009
- 2009-12-16 US US12/639,645 patent/US8436051B2/en active Active
-
2010
- 2010-01-19 CA CA2690450A patent/CA2690450A1/en not_active Abandoned
- 2010-12-16 MX MX2012006902A patent/MX2012006902A/es not_active Application Discontinuation
- 2010-12-16 CA CA2784772A patent/CA2784772A1/en not_active Abandoned
- 2010-12-16 CN CN2010800632711A patent/CN102970971A/zh active Pending
- 2010-12-16 RU RU2012125186/15A patent/RU2012125186A/ru not_active Application Discontinuation
- 2010-12-16 KR KR1020127018382A patent/KR20120104604A/ko not_active Withdrawn
- 2010-12-16 JP JP2012544851A patent/JP2013514979A/ja active Pending
- 2010-12-16 AU AU2010339837A patent/AU2010339837A1/en not_active Abandoned
- 2010-12-16 WO PCT/US2010/060849 patent/WO2011084638A2/en not_active Ceased
- 2010-12-16 SG SG2012041356A patent/SG181169A1/en unknown
- 2010-12-16 EP EP10816342A patent/EP2512443A2/en not_active Withdrawn
-
2012
- 2012-06-14 IL IL220397A patent/IL220397A0/en unknown
- 2012-06-15 ZA ZA2012/04422A patent/ZA201204422B/en unknown
- 2012-06-15 CL CL2012001636A patent/CL2012001636A1/es unknown
-
2013
- 2013-04-10 US US13/859,898 patent/US9884018B2/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10323320B2 (en) | 2008-04-24 | 2019-06-18 | Oerlikon Surface Solutions Ag, Pfäffikon | Method for producing metal oxide layers of predetermined structure through arc vaporization |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2512443A2 (en) | 2012-10-24 |
| ZA201204422B (en) | 2013-08-28 |
| JP2013514979A (ja) | 2013-05-02 |
| US8436051B2 (en) | 2013-05-07 |
| CL2012001636A1 (es) | 2012-10-12 |
| SG181169A1 (en) | 2012-07-30 |
| US9884018B2 (en) | 2018-02-06 |
| CN102970971A (zh) | 2013-03-13 |
| WO2011084638A2 (en) | 2011-07-14 |
| WO2011084638A3 (en) | 2012-04-05 |
| AU2010339837A1 (en) | 2012-06-28 |
| IL220397A0 (en) | 2012-08-30 |
| KR20120104604A (ko) | 2012-09-21 |
| RU2012125186A (ru) | 2014-01-27 |
| CA2784772A1 (en) | 2011-07-14 |
| US20130231310A1 (en) | 2013-09-05 |
| CA2690450A1 (en) | 2011-06-16 |
| US20100105639A1 (en) | 2010-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012006902A (es) | Supositorio de mesalamina. | |
| JP5685540B2 (ja) | 咀嚼可能なゲル化エマルジョン | |
| KR20020048424A (ko) | 폐경기 여성용 조성물 | |
| CA2963952C (en) | Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states | |
| JPH09508117A (ja) | 反芻動物に有益な物質を投与するための器具 | |
| US20090264386A1 (en) | Mesalamine suppository | |
| US7541384B2 (en) | Mesalamine suppository | |
| US20210322360A1 (en) | Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states | |
| CN102000341A (zh) | 在栓剂组合物中的聚氧化乙烯及基质型表面活性剂 | |
| WO2000067797A1 (en) | Composition providing a sustained release of l-histidine and methods of manufacture thereof | |
| JP2023113819A (ja) | 脂質組み合わせ | |
| KR20190134671A (ko) | 체중을 감소시키고 체지방을 감소시키기 위한 조성물 및 그의 제약 생성물 및 적용 | |
| CN115768270A (zh) | 膳食组合物和方法 | |
| CA3177523A1 (en) | Ademetionine and cannabidiol based solid pharmaceutical composition and method for preparing it | |
| RS59176B1 (sr) | Direktni granulat sa aktivnim sredstvom za produženo oslobađanje | |
| PL233287B1 (pl) | Granulat zawierający związek maślanu, sposób jego otrzymywania oraz jego zastosowanie | |
| JP7064292B2 (ja) | ロキソプロフェン又はその塩及びビタミンｅを含有する経口用医薬組成物 | |
| CN107847435A (zh) | 用于治疗直肠的炎性变化的药物制剂 | |
| JP6647902B2 (ja) | 徐放性顆粒剤 | |
| EP4626399A1 (en) | Estriol vaginal ring | |
| EA046287B1 (ru) | Комбинации липидов | |
| CN109646629A (zh) | 一种治疗肾阴亏损型老年性阴道炎的颗粒剂 | |
| TW202128185A (zh) | 經穩定之修飾釋放維他命d調配物及其服用方法 | |
| JPS607601B2 (ja) | 医薬用カプセル基剤 | |
| TW201934117A (zh) | 經穩定之修飾釋放維他命d調配物及其服用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |